Dr. David J. Perry

Jeanny Aragon-Ching is an Oncologist and a Hematologist in Alexandria, Virginia. Dr. Aragon-Ching is rated as a Distinguished provider by MediFind in the treatment of Clear Cell Sarcoma. Her top areas of expertise are Prostate Cancer, Urothelial Cancer, Bladder Cancer, Orchiectomy, and Prostatectomy. Dr. Aragon-Ching is currently accepting new patients.

Michael Atkins is an Oncologist in Washington, Washington, D.c.. Dr. Atkins is rated as an Advanced provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Wilms Tumor, Familial Wilms Tumor 2, Renal Cell Carcinoma (RCC), and Clear Cell Sarcoma.

Dr. Mark Markowski is a medical oncologist at the Kimmel Cancer Center at Sibley Memorial Hospital, as well as an Associate Professor in the Department of Oncology at Johns Hopkins University School of Medicine. Dr. Markowski participates in multidisciplinary clinics at Sibley and The Johns Hopkins Hospital, and sees patients in the genitourinary clinics of both hospitals. Dr. Markowski treats numerous types of cancers, with a specialty in prostate and kidney cancers. Dr. Markowski earned his medical degree and Ph.D. in tumor biology at Georgetown University School of Medicine. He completed a residency in internal medicine at Columbia University, followed by a medical oncology fellowship at Johns Hopkins Hospital. Dr. Markowski previously served as a research associate at the Lombardi Comprehensive Cancer Center at Georgetown University. His research interests focus on early phase drug development for prostate cancer, as well a non-castrating therapies for patients with metastatic disease. Dr. Markowski is currently conducting research with funding from a Department of Defense Prostate Cancer Research Program Award and a Challenge Award from the Prostate Cancer Foundation, which focuses on new treatment strategies for prostate cancer patients. Dr. Markowski is rated as a Distinguished provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), Wilms Tumor, Hormone Replacement Therapy (HRT), and Prostatectomy.